|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Investor protection and corporate governance显示文摘 | Rafael La Porta Florencio Lopez-de-Silanes Andrei Shleifer Robert Vishny | 2000 | Journal of Financial Economics2000，，1： | 16 |
| 2 | Agency Problems and Dividend Policies around the World显示文摘 | RafaelLa Porta FlorencioLopez‐de‐Silanes AndreiShleifer Robert W.Vishny | 2007 | The Journal of Finance2007，，1： | 12 |
| 3 | Investor Protection and Corporate Valuation显示文摘 | RafaelLa porta FlorencioLopez‐De‐Silanes AndreiShleifer RobertVishny | 2002 | The Journal of Finance2002，，3： | 9 |
| 4 | 关于在稳固的肿瘤的癌症干细胞的想法显示文摘 Cancer chemotherapy efficacy is frequently impaired by either intrinsic or acquired tumor resistance.A fundamental problem in cancer research is identifying the cell type that is capable of sustaining neoplastic growth and its origin from normal tissue cells.In recent years,the cancer stem cell(CSC) theory has changed the classical view of tumor growth and therefore the therapeutic perspective.Overcoming intrinsic and acquired resistance of cancer stem/progenitor cells to current clinical treatments represents a major challenge in treating and curing the most aggressive and metastatic cancers.On the other hand,the identification of CSCs in vivo and in vitro relies on specific surface markers that should allow the sorting cancer cells into phenotypically distinct subpopulations.In the present review,recent papers published on CSCs in solid tumors(breast,prostate,brain and melanoma) are discussed,highlighting critical points such as the choice of markers to sort CSCs and mouse models to demonstrate that CSCs are able to replicate the original tumor.A discussion of the possible role of aldehyde dehydrogenase and CXCR6 biomarkers as signaling molecules in CSCs and normal stem cells is also discussed.The author believes that efforts have to be made to investigate the functional and biological properties of putative CSCs in cancer.Developing diagnostic/prognostic tools to follow cancer development is also a challenge.In this connection it would be useful to develop a multidisciplinary approach combining mathematics,physics and biology which merges experimental approaches and theory.Biological models alone are probably unable to resolve the problem completely. | Caterina AM La Porta | 2012 | World Journal of Stem Cells2012，4，3： | 8 |
| 5 | Cytomegalovirus frequency in neonatal intrahepatic cholestasis determined by serology, histology, immunohistochemistry and PCR显示文摘AIM: To determine cytomegalovirus (CMV) frequency in neonatal intrahepatic cholestasis by serology, histological revision (searching for cytomegalic cells), immunohistochemistry, and polymerase chain reaction (PCR), and to verify the relationships among these methods.METHODS: The study comprised 101 non-consecutive infants submitted for hepatic biopsy between March 1982 and December 2005. Serological results were obtained from the patient's f iles and the other methods were performed on paraffin-embedded liver samples from hepatic biopsies. The following statistical measures were calculated: frequency, sensibility, specif ic positive predictive value, negative predictive value, and accuracy.RESULTS: The frequencies of positive results were as follows: serology, 7/64 (11%); histological revision, 0/84; immunohistochemistry, 1/44 (2%), and PCR, 6/77 (8%). Only one patient had positive immunohistochemical fi ndings and a positive PCR. The following statistical measures were calculated between PCR and serology: sensitivity, 33.3%; specificity, 88.89%; positive predictive value, 28.57%; negative predictive value, 90.91%; and accuracy, 82.35%. CONCLUSION: The frequency of positive CMV varied among the tests. Serology presented the highest positive frequency. When compared to PCR, the sensitivity and positive predictive value of serology were low. | Maria Angela Bellomo-Brandao Paula D Andrade Sandra CB Costa Cecilia AF Escanhoela Jose Vassallo Gilda Porta Adriana MA De Tommaso Gabriel Hessel | 2009 | World Journal of Gastroenterology2009，15，27： | 8 |
| 6 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial显示文摘 | Jordi Bruix Jean-Luc Raoul Morris Sherman Vincenzo Mazzaferro Luigi Bolondi Antonio Craxi Peter R. Galle Armando Santoro Michel Beaugrand Angelo Sangiovanni Camillo Porta Guido Gerken Jorge A. Marrero Andrea Nadel Michael Shan Marius Moscovici Dimitris Vo | 2012 | Journal of Hepatology2012，，4： | 6 |
| 7 | Government Ownership of Banks显示文摘 | RafaelLa Porta FlorencioLopez‐De‐Silanes AndreiShleifer | 2002 | The Journal of Finance2002，，1： | 6 |
| 8 | Subcapsular hepatic haematoma of the right lobe following endoscopic retrograde cholangiopancreatography: Case report and literature review显示文摘Sub capsular hepatic haematoma is a rare complication after endoscopic retrograde cholangiopancreatography(ERCP). Exact pathological mechanism is still unclear and few reports are nowadays available in literature. We report the case of a 58-year-old woman with recurrent episodes of upper abdominal pain, nausea and vomiting. On the basis of laboratory exams, abdomen ultrasound and magnetic resonance imaging she was diagnosed with a common bile duct stone. Endoscopic biliary sphincterotomy was performed. On the following day the patient complaint severe abdominal pain with rebound and hemodynamic instability. A computed tomography scan reveal a 14 cm × 6 cm × 19 cm subcapsular hepatic haematoma on the right lobe that was successfully managed via percutaneous embolization. Sub capsular liver haematoma is a rare life threatening complication after ERCP that should be managed according to patients' haemodynamic and clinic. | Marco Antonio Zappa Alberto Aiolfi Ilaria Antonini Cinzia Domenica Musolino Andrea Porta | 2016 | World Journal of Gastroenterology2016，22，17： | 5 |
| 9 | The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages显示文摘 | Paola Allavena Antonio Sica Graziella Solinas Chiara Porta Alberto Mantovani | 2007 | Critical Reviews in Oncology and Hematology2007，，1： | 5 |
| 10 | Legal Determinants of External Finance显示文摘 | RAFAEL PORTA FLORENCIO LOPEZ‐DE‐SILANES ANDREI SHLEIFER ROBERT W. VISHNY | 1997 | The Journal of Finance1997，，3： | 4 |
| 11 | Do Institutions Cause Growth?显示文摘 | Edward L. Glaeser Rafael La Porta Florencio Lopez-de-Silanes Andrei Shleifer | 2004 | Journal of Economic Growth2004，，3： | 4 |
| 12 | The law and economics of self-dealing显示文摘 | Simeon Djankov Rafael La Porta Florencio Lopez-de-Silanes Andrei Shleifer | 2008 | Journal of Financial Economics2008，，3： | 3 |
| 13 | Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib显示文摘Even though Sorafenib has radically changed the natural history of those hepatocellular carcinoma patients who are not amenable for curative treatments, further therapeutic improvements are badly needed. As it was for Sorafenib, our increasingly refined understanding of the complex mechanisms underlying HCC carcinogenesis are the starting point for the future development of such treatments. Presently, a number of molecularly targeted agents are in different stages of development for this once orphan cancer. Indeed, several pathways are presently being explored to identify potentially active drugs, including epidermal growth factor receptor, vascular endothelial growth factor/vascular endothelial growth factor receptors, mammalian target of rapamycin, phosphatidyl-inositol-3-kinase/Akt, insulin growth factor, Aurora kinase, Wnt/β-catenin, retinoic acid receptor and hepatocyte growth factor/C-Met. This review is aimed at addressing the results obtained so far with these newer drugs, also considering the challenges we shall face in the near future, including the issue of response evaluation and identification of predictive/ prognostic biomarkers. | Camillo Porta Chiara Paglino | 2010 | World Journal of Hepatology2010，2，3： | 3 |
| 14 | Investor protection and corporate governance显示文摘 | Rafael La Porta Florencio Lopez-de-Silanes Andrei Shleifer Robert Vishny | 2000 | Journal of Financial Economics2000，，1： | 3 |
| 15 | Investor Protection and Corporate Valuation显示文摘 | RafaelLa porta FlorencioLopez‐De‐Silanes AndreiShleifer RobertVishny | 2002 | The Journal of Finance2002，，3： | 3 |
| 16 | Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy显示文摘In 2017,immune response evaluation criteria in solid tumors(iRECIST)were introduced to validate radiologic and clinical interpretations and to better analyze tumor’s response to immunotherapy,considering the different time of following and response,between this new therapy compared to the standard one.However,even if the iRECIST are worldwide accepted,to date,different aspects should be better underlined and well reported,especially in clinical practice.Clinical experience has demonstrated that in a non-negligible percentage of patients,it is challenging to determine the correct category of response(stable disease,progression disease,partial or complete response),and consequently,to define which is the best management for those patients.Approaching radiological response in patients who underwent immunotherapy,a new uncommon kind of target lesions behavior was found.This phenomenon is mainly due to the different mechanisms of action of immunotherapeutic drug.Therefore,new groups of response have been described in clinical practice,defined as“atypical responses,”and categorized into three new groups:pseudoprogression,hyperprogression,and dissociated response.This review summarizes and reports these patterns,helping clinicians and radiologists get used to atypical responses,in order to identify patients that respond best to treatment. | Davide Ippolito Cesare Maino Maria Ragusi Marco Porta Davide Gandola Cammillo Talei Franzesi Teresa Paola Giandola Sandro Sironi | 2021 | World Journal of Clinical Oncology2021，12，5： | 3 |
| 17 | The network analysis of urban streets: A dual approach显示文摘 | Sergio Porta Paolo Crucitti Vito Latora | 2006 | Physica A: Statistical Mechanics and its Applications2006，，2： | 3 |
| 18 | The new comparative economics显示文摘 | Simeon Djankov Edward Glaeser Rafael La Porta Florencio Lopez-de-Silanes Andrei Shleifer | 2003 | Journal of Comparative Economics2003，，4： | 2 |
| 19 | 用于北美的ALP-45DP型双动力源机车显示文摘北美地区早已存在同时具有内燃和电力双动力的机车,即双动力源干线机车。但这种机车并没有得以有效运用。将内燃牵引装备和电力牵引装备(从架空线电网获取电流)装在一台机车上是很困难、很复杂的,因而以这种方式制造的机车并不可靠。但是庞巴迪(Bombardier)公司现在制造的新型ALP-45DP型机车有可能成为具备高可靠性的机车典范。设计这种机车的目的是,其牵引的列车可使尽可能多的乘客不用换乘,从而可以实现'一座到站'(或'一座到底','OneSeat-Ride')。该机车可以在运输密度较低的非电气化铁路上运行,同时在通过隧道、市内车站时,仍能利用架空线电网运行。该机车在技术上综合了庞巴迪公司久经考验的ALP-46A型基型机车、TRAXX MS多流制机车和TRAXX DE内燃机车的动力传动技术。新机车的最高速度在内燃牵引工况达160 km/h,在电力牵引工况可达200 km/h。机车总重量只有128t。文中详细介绍了双动力源机车从理念提出到实现的过程、机车总体设计的酝酿、机车的性能和技术参数、机车在技术和重量方面遇到的挑战、电力和内燃两种牵引方式的转换原理以及关于机车检验、交货和投入运用的情况。 | Romann Porta Bernhard Kund 韩才元 | 2013 | 国外铁道机车与动车2013，，5： | 2 |
| 20 | The law and economics of self-dealing显示文摘 | Simeon Djankov Rafael La Porta Florencio Lopez-de-Silanes Andrei Shleifer | 2008 | Journal of Financial Economics2008，，3： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员